Please login to the form below

Not currently logged in
Email:
Password:

Bicycle Therapeutics appoints former Pfizer VP Maria Koehler

She joins the UK biotech as its chief medical officer

Maria KoehlerBicycle Therapeutics has appointed Maria Koehler as its chief medical officer, a role that will see her lead clinical strategy and oversee operational functions for the UK-headquartered biotech’s clinical development team.

Koehler has two decades of industry experience and joins the group from Pfizer, where she was vice president of strategy, innovation and collaborations for its oncology business unit.

Dr Kevin Lee, chief executive officer at Bicycle Therapeutics, said: “As chief medical officer, Maria will play a pivotal role in furthering our mission to transform the treatment regimens for cancer and other diseases.

“Maria has an exemplary track record, both as an oncology clinician and researcher, and as a drug development expert and we look forward to drawing on her breadth of experience in the development, registration and launch of oncology drugs.”

Prior to joining Pfizer, Koehler was the group leader for the medicine development centre of GlaxoSmithKline Oncology, and a senior medical director oncology research and development at AstraZeneca.

She said: “This is a tremendous opportunity to contribute to the clinical development of Bicycles, which are a truly innovative new class of cancer treatment with broad potential to make a life-changing impact on patients with cancer.

“I’m eager to work with the Bicycle team to bring these unique and powerful therapies to patients.”

4th October 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...